News
Cassiopea SpA announces preparing delisting of shares on SIX Swiss Exchange
Cassiopea SpA announces preparing delisting of shares on SIX Swiss Exchange
SpA kündigt die Vorbereitung der Dekotierung der Aktien an der SIX Swiss Exchange an
SpA kündigt die Vorbereitung der Dekotierung der Aktien an der SIX Swiss Exchange an
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
DGAP-News: NanoRepro AG: 94,1 % statt 76,5 % - Handelsblatt korrigiert Sensitivität des NanoRepro Schnelltests nach oben
DGAP-News: NanoRepro AG: 94,1 % statt 76,5 % - Handelsblatt korrigiert Sensitivität des NanoRepro Schnelltests nach oben
DGAP-News: BRAIN Biotech AG veröffentlicht Geschäftsbericht für das Finanzjahr 2020/21
DGAP-News: BRAIN Biotech AG veröffentlicht Geschäftsbericht für das Finanzjahr 2020/21
DGAP-News: BRAIN Biotech AG publishes Annual Report for FY 2020/21
DGAP-News: BRAIN Biotech AG publishes Annual Report for FY 2020/21
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas als patentierbare Technologie eingestuft
DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas als patentierbare Technologie eingestuft
DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
DGAP-News: NanoRepro AG: Klinische Studien zur Sensitivität der Schnelltests bei der Omikron-Variante
DGAP-News: NanoRepro AG: Klinische Studien zur Sensitivität der Schnelltests bei der Omikron-Variante
Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution
Edison Investment Research Limited: Agronomics (ANIC) Initiation - At the forefront of a new agrarian revolution
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change